Citations (116)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Sebastiano Mercadante. (2018) Treating breakthrough pain in oncology. Expert Review of Anticancer Therapy 18:5, pages 445-449.
Read now
Read now
Sebastiano Mercadante. (2017) Fentanyl products in the management of episodic pain in the cancer patient. Expert Review of Quality of Life in Cancer Care 2:1, pages 41-45.
Read now
Read now
Andrew Chang, Eric J. Roeland, Rabia S. Atayee, Carolyn Revta & Joseph D. Ma. (2015) Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care. Journal of Pain & Palliative Care Pharmacotherapy 29:3, pages 247-260.
Read now
Read now
Dulce Rogríguez, Gerard Urrutia, Yolanda Escobar, Jordi Moya & Maite Murillo. (2015) Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review. Journal of Pain & Palliative Care Pharmacotherapy 29:3, pages 228-246.
Read now
Read now
Gerhard Müller-Schwefe, Karsten Ahlbeck, Dominic Aldington, Eli Alon, Stefano Coaccioli, Flaminia Coluzzi, Frank Huygen, Wolfgang Jaksch, Eija Kalso, Magdalena Kocot-Kępska, Hans-Georg Kress, Ana Cristina Mangas, Cesar Margarit Ferri, Bart Morlion, Andrew Nicolaou, Concepción Pérez Hernández, Joseph Pergolizzi, Michael Schäfer & Patrick Sichère. (2014) Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements. Current Medical Research and Opinion 30:9, pages 1895-1908.
Read now
Read now
Sebastiano Mercadante & Antonino Giarratano. (2014) Assessing age and gender in studies of breakthrough pain medications. Current Medical Research and Opinion 30:7, pages 1353-1356.
Read now
Read now
Howard S Smith. (2013) Considerations in selecting rapid-onset opioids for the management of breakthrough pain. Journal of Pain Research 6, pages 189-200.
Read now
Read now
Donald R Taylor. (2013) Single-dose fentanyl sublingual spray for breakthrough cancer pain. Clinical Pharmacology: Advances and Applications 5, pages 131-141.
Read now
Read now
Sebastiano Mercadante, Giovanna Prestia & Alessandra Casuccio. (2013) The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen. Current Medical Research and Opinion 29:11, pages 1527-1532.
Read now
Read now
Eric Prommer & Brandy Ficek. (2012) Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain. Patient Preference and Adherence 6, pages 465-475.
Read now
Read now
Richard Rauck, Lowell Reynolds, Jonathan Geach, Janet Bull, Lisa Stearns, Morris Scherlis, Neha Parikh & Larry Dillaha. (2012) Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Current Medical Research and Opinion 28:5, pages 859-870.
Read now
Read now
Mellar P Davis. (2011) Fentanyl for breakthrough pain: a systematic review. Expert Review of Neurotherapeutics 11:8, pages 1197-1216.
Read now
Read now
Kyriaki Mystakidou, Irene Panagiotou & Athanasios Gouliamos. (2011) Fentanyl nasal spray for the treatment of cancer pain. Expert Opinion on Pharmacotherapy 12:10, pages 1653-1659.
Read now
Read now
Michael A. Überall & Gerhard H.H. Müller-Schwefe. (2011) Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Current Medical Research and Opinion 27:7, pages 1385-1394.
Read now
Read now
Srinivas Nalamachu, David Hassman, Mark S. Wallace, Sam Dumble, Rob Derrick & Julian Howell. (2011) Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Current Medical Research and Opinion 27:3, pages 519-530.
Read now
Read now
Articles from other publishers (101)
Hironori MawatariTakuya ShinjoTatsuya MoritaHiroyuki KoharaKinomi Yomiya. (2022) Revision of Pharmacological Treatment Recommendations for Cancer Pain: Clinical Guidelines from the Japanese Society of Palliative Medicine. Journal of Palliative Medicine 25:7, pages 1095-1114.
Crossref
Crossref
. 2022. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
511
774
.
Masoud Hashemi, Alireza Zali, Ebrahim Golmakani, Mohammad Hossein Delshad, Mahdi Shadnoush & Mohammad-Esmaeil Akbari. (2021) Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. DARU Journal of Pharmaceutical Sciences 29:1, pages 51-59.
Crossref
Crossref
Youn Seon Choi, Su-Jin Koh, Woo Kyun Bae, Se Hyung Kim, Seong Hoon Shin, So Yeon Oh, Sang Byung Bae, Yaewon Yang, Eun-Kee Song, Yoon Young Cho, Pyung Bok Lee, Ho-Suk Oh, Sang Won Park & Jin Seok Ahn. (2021) Observational study of efficacy, safety, and tolerability of fentanyl in Korean cancer patients (OASIS). Medicine: Case Reports and Study Protocols 2:3, pages e0088.
Crossref
Crossref
Sebastiano Mercadante, Vincenzo Restivo & Alessandra Casuccio. (2019) Effects of age and gender in patients receiving doses of opioids for breakthrough pain proportional to background opioid doses. Supportive Care in Cancer 28:8, pages 3813-3818.
Crossref
Crossref
Xue-Bin Yan. 2019. From Conventional to Innovative Approaches for Pain Treatment. From Conventional to Innovative Approaches for Pain Treatment.
Francesca Ricchini, Augusto Caraceni, Ernesto Zecca, Alessandra Pigni, Fabio Centurioni, Andrea Manzoni, Stein Kaasa & Cinzia Brunelli. (2019) Effect of Opioid Exposure on Efficacy and Tolerability of Sublingual Fentanyl and Subcutaneous Morphine for Severe Cancer Pain Episodes. Secondary Analysis From a Double-Blind Double-Dummy, Randomized Trial. Journal of Pain and Symptom Management 58:4, pages 587-595.
Crossref
Crossref
Jordi Guitart, María Isabel Vargas, Vicente De Sanctis, Jordi Folch, Rafael Salazar, José Fuentes, Joan Coma, Julia Ferreras, Jordi Moya, Albert Tomás, Pere Estivill, Francisco Rodelas, Antonio Javier Jiménez & Almudena Sanz. (2019) Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets. Drugs in R&D 19:3, pages 247-254.
Crossref
Crossref
Joanna Brząkała & Wojciech Leppert. (2019) The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients. Pharmacological Reports 71:3, pages 438-442.
Crossref
Crossref
Ayman Abdalmaksoud Yousef & Ashraf Elsayed Alzeftawy. (2018) The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study. Supportive Care in Cancer 27:6, pages 2171-2177.
Crossref
Crossref
Rei Tanaka, Hiroshi Ishikawa, Tetsu Sato, Michihiro Shino, Katsuhiro Omae, Tetsumi Sato & Iwao Osaka. (2018) Safety profile of prophylactic rescue dosing of immediate-release oral opioids in cancer patients. Journal of Pharmaceutical Health Care and Sciences 4:1.
Crossref
Crossref
Jordi Guitart, María Isabel Vargas, Vicente De Sanctis, Jordi Folch, Rafael Salazar, José Fuentes, Joan Coma, Julia Ferreras, Jordi Moya, Albert Tomás, Pere Estivill, Francisco Rodelas, Antonio Javier Jiménez & Almudena Sanz. (2018) Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication. Drugs in R&D 18:2, pages 119-128.
Crossref
Crossref
Robert Janknegt, Marieke van den Beuken, Sjouke Schiere, Michael Überall, Roger Knaggs, Jaquie Hanley & Morten Thronaes. (2018) Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis. European Journal of Hospital Pharmacy 25:3, pages e2-e2.
Crossref
Crossref
Luca Miceli, Rym Bednarova, Luigi Vetrugno, Marco Cascella & Arturo Cuomo. (2018) Is the limit of 60 mg of oral morphine equivalent daily dose still actual for the access to rapid onset opioids therapy?. Current Problems in Cancer 42:3, pages 367-368.
Crossref
Crossref
Zahra Shoormeij, Azade Taheri & Alireza Homayouni. (2018) Preparation and physicochemical characterization of meloxicam orally fast disintegration tablet using its solid dispersion. Brazilian Journal of Pharmaceutical Sciences 53:4.
Crossref
Crossref
Q. Liu, L.-L. Gao, Y.-L. Dai, Y.-X. Li, Y. Wang, C.-F. Bai, G.-X. Mu, X.-M. Chai, W.-J. Han, L.-J. Zhou, Y.-J. Zhang, L. Tang, J. Liu & J.-Q. Yu. (2018) Nitrous oxide/oxygen mixture for analgesia in adult cancer patients with breakthrough pain: A randomized, double-blind controlled trial. European Journal of Pain 22:3, pages 492-500.
Crossref
Crossref
. 2018. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
447
696
.
Samir Sheth, Mark Holtsman & Gagan Mahajan. 2018. Essentials of Pain Medicine. Essentials of Pain Medicine
373
384.e2
.
Maxie Blasini, Nicole Corsi & Luana Colloca. 2018. Handbook of Pain and Palliative Care. Handbook of Pain and Palliative Care
317
336
.
Leonie Wagner-Hattler, Katharina Wyss, Joachim Schoelkopf, Jörg Huwyler & Maxim Puchkov. (2017) In vitro characterization and mouthfeel study of functionalized calcium carbonate in orally disintegrating tablets. International Journal of Pharmaceutics 534:1-2, pages 50-59.
Crossref
Crossref
Lucy Coombes, Kimberley Burke & Anna-Karenia Anderson. (2017) The use of rapid onset fentanyl in children and young people for breakthrough cancer pain. Scandinavian Journal of Pain 17:1, pages 256-259.
Crossref
Crossref
Jordi Guitart, María Isabel Vargas, Vicente De Sanctis, Jordi Folch, Rafael Salazar, José Fuentes, Joan Coma, Julia Ferreras, Jordi Moya, Albert Tomás, Pere Estivill, Francisco Rodelas, Antonio Javier Jiménez & Almudena Sanz. (2017) Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study. Drugs in R&D 17:3, pages 419-425.
Crossref
Crossref
Jeannine Brant, Barbara Rodgers, Eva Gallagher & Thiruppavai Sundaramurthi. (2017) Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
. Clinical Journal of Oncology Nursing 21:3, pages 71-80.
Crossref
Crossref
Stephan A. Schug & Sonya Ting. (2017) Fentanyl Formulations in the Management of Pain: An Update. Drugs 77:7, pages 747-763.
Crossref
Crossref
Ernesto ZeccaCinzia BrunelliFabio CenturioniAndrea ManzoniAlessandra PigniAugusto Caraceni. (2017) Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial. Journal of Clinical Oncology 35:7, pages 759-765.
Crossref
Crossref
Saadya A. Tayel, Mohamed A. El Nabarawi, Maha M. Amin & Mohamed H. H. AbouGhaly. (2016) Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets. AAPS PharmSciTech 18:2, pages 410-423.
Crossref
Crossref
Toshihiro Shida, Mayumi Yamakawa, Sachiko Suzuki & Tadashi Shiraishi. (2017) A Case Report on the Use of the Rapid-onset Opioid Fentanyl Resulting in Numbness and Pain in the Mouth and Taste Disturbance. Palliative Care Research 12:2, pages 526-529.
Crossref
Crossref
Sebastiano Mercadante & Russell K. Portenoy. (2016) Breakthrough cancer pain: twenty-five years of study. Pain 157:12, pages 2657-2663.
Crossref
Crossref
Arjun Seth, Il Gyu Kong, Su-Hyun Lee, Jin-Young Yang, Yong-Soo Lee, Yeji Kim, Nani Wibowo, Anton P.J. Middelberg, Linda H.L. Lua & Mi-Na Kweon. (2016) Modular virus-like particles for sublingual vaccination against group A streptococcus. Vaccine 34:51, pages 6472-6480.
Crossref
Crossref
Harold Minkowitz, Janet Bull, R. Charles Brownlow, Neha Parikh & Richard Rauck. (2016) Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain. Supportive Care in Cancer 24:6, pages 2669-2675.
Crossref
Crossref
Andrew Davies, Gill Mundin, Joanna Vriens, Kath Webber, Alison Buchanan & Melanie Waghorn. (2016) The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain. Journal of Pain and Symptom Management 51:3, pages 538-545.
Crossref
Crossref
Juan Pérez-Cajaraville. (2016) Calidad de vida y satisfacción del paciente anciano no oncológico con dolor irruptivo tratado con fentanilo sublingual. Revista de la Sociedad Española del Dolor 23.
Crossref
Crossref
Jordi Guitart, María Isabel Vargas, Vicente De Sanctis, Jordi Folch, Rafael Salazar, José Fuentes, Jordi Coma, Julia Ferreras, Jordi Moya, Albert Tomás, Pere Estivill, Francisco Rodelas & Antonio Javier Jiménez. (2015) Sublingual Fentanyl Tablets for Relief of Breakthrough Pain in Cancer Patients and Association with Quality-of-Life Outcomes. Clinical Drug Investigation 35:12, pages 815-822.
Crossref
Crossref
Giovambattista Zeppetella & Andrew N Davies. (2015) Opioids for the management of breakthrough pain in cancer patients. Cochrane Database of Systematic Reviews.
Crossref
Crossref
R. Sperlinga, S. Campagna, A. Berruti, P. Laciura, I. Ginosa, S. Paoletti, P.L. Giuliano, M. Tucci, R. Rosato, G.V. Scagliotti & A. Saini. (2015) Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain. European Journal of Pain 19:7, pages 881-888.
Crossref
Crossref
Richard RauckNeha ParikhLarry DillahaJerry BarkerLisa Stearns. (2015) Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain. Pain Practice 15:6, pages 554-563.
Crossref
Crossref
Antonio J. García Ruiz, José Luis Pérez Aguiar & Nuria García-Agua Soler. (2015) Gasto económico del tratamiento del dolor irruptivo. Medicina Paliativa 22, pages 62-70.
Crossref
Crossref
Rafael López Castro. (2015) Prevalencia del dolor en enfermos oncológicos. Dolor irruptivo. Medicina Paliativa 22, pages 2-9.
Crossref
Crossref
Sebastiano Mercadante, Renato Vellucci, Arturo Cuomo, Claudio Adile, Andrea Cortegiani, Alessandro Valle, Patrizia Villari & Alessandra Casuccio. (2014) Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Supportive Care in Cancer 23:5, pages 1349-1354.
Crossref
Crossref
Giovambattista Zeppetella, Andrew Davies, Indra Eijgelshoven & Jeroen P. Jansen. (2015) Une méta-analyse en réseau de l’efficacité des analgésiques opioïdes dans la prise en charge des épisodes d’accès douloureux paroxystiques d’origine cancéreuse. Douleurs : Evaluation - Diagnostic - Traitement 16:2, pages 61-76.
Crossref
Crossref
Morten Thronæs, Lars Popper, Martin Eeg, Ellen Jaatun, Magnar Kvitberg & Stein Kaasa. (2015) Efficacy and Tolerability of Intranasal Fentanyl Spray in Cancer Patients With Breakthrough Pain. Clinical Therapeutics 37:3, pages 585-596.
Crossref
Crossref
Luz Cánovas-Martínez, José J. Carceller-Ruiz, Pilar Díaz-Parada, Gustavo Illodo-Miramontes, Enrique Freire-Vila, Aurora De la Iglesia-López, Belén García Iglesias, Beatriz López-Ulloa, Enrique Domínguez-Suárez & Alberto Camba-Rodríguez. (2015) Efficacy and Safety of Sublingual Fentanyl Tablets for the Management of Breakthrough Pain in Patients with Chronic Musculoskeletal Pain with Neuropathic Component: Multicenter Prospective Study. Clinical Drug Investigation 35:3, pages 169-177.
Crossref
Crossref
C.H. Martini, P. Proto, E. Olofsen, M. Velzen, L. Aarts, A. Dahan & M. Niesters. (2015) A randomized controlled trial and novel mathematical analysis of the analgesic effect of oxycodone versus paracetamol orodispersible tablets. European Journal of Pain 19:3, pages 295-304.
Crossref
Crossref
Naohito Shimoyama, Ikuo Gomyo, Nobuyuki Katakami, Masakuni Okada, Nobuyuki Yukitoshi, Eri Ohta & Megumi Shimoyama. (2014) Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial. International Journal of Clinical Oncology 20:1, pages 198-206.
Crossref
Crossref
C. Takigawa, F. Goto, S. Tanda, Y. Shima, K. Yomiya, M. Matoba, I. Adachi, T. Yoshimoto & K. Eguchi. (2014) Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation. Japanese Journal of Clinical Oncology 45:1, pages 67-74.
Crossref
Crossref
. 2015. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
417
651
.
Theodore H. Stanley. (2014) The Fentanyl Story. The Journal of Pain 15:12, pages 1215-1226.
Crossref
Crossref
A. De Graeff. (2014) Diagnostiek en behandeling van pijn bij kanker. Mednet 7:8, pages 36-39.
Crossref
Crossref
K.B. Gombert-Handoko. (2014) A Randomized, Placebo-controlled Study of a New Sublingual Formulation of Fentanyl Citrate (Fentanyl Ethypharm) for Breakthrough Pain in Opioid-treated Patients With Cancer. Clinical Therapeutics 36:11, pages 1704.
Crossref
Crossref
Matthew G. Kestenbaum, Agustin O. Vilches, Stephanie Messersmith, Stephen R. Connor, Perry G. Fine, Brian Murphy, Malene Davis & J. Cameron Muir. (2014) Alternative Routes to Oral Opioid Administration in Palliative Care: A Review and Clinical Summary. Pain Medicine 15:7, pages 1129-1153.
Crossref
Crossref
Paul Telfer, Nawal Bahal, Alice Lo & Joanne Challands. (2014) Management of the acute painful crisis in sickle cell disease- a re-evaluation of the use of opioids in adult patients. British Journal of Haematology 166:2, pages 157-164.
Crossref
Crossref
Furio Zucco, Cesare Bonezzi & Diego Fornasari. (2014) Breakthrough Cancer Pain (BTcP): a Synthesis of Taxonomy, Pathogenesis, Therapy, and Good Clinical Practice in Adult Patients in Italy. Advances in Therapy 31:7, pages 657-682.
Crossref
Crossref
Toshifumi Kosugi, Sasagu Hamada, Chizuko Takigawa, Katsunori Shinozaki, Hiroshi Kunikane, Fumio Goto, Shigeru Tanda, Yasuo Shima, Kinomi Yomiya, Motohiro Matoba, Isamu Adachi, Tetsusuke Yoshimoto & Kenji Eguchi. (2014) A Randomized, Double-Blind, Placebo-Controlled Study of Fentanyl Buccal Tablets for Breakthrough Pain: Efficacy and Safety in Japanese Cancer Patients. Journal of Pain and Symptom Management 47:6, pages 990-1000.
Crossref
Crossref
Rafael López, Juan Jesús Cruz, Rafael Gálvez, Yolanda Escobar, Joaquim Juliá, Ana Mañas, Francisco Zaragozá, Cesar Margarit, Ana Casas, Antonio Antón & Yolanda Riesgo. (2013) Análisis de impacto presupuestario del uso de fentanilo intranasal en pectina para el tratamiento del dolor irruptivo oncológico. PharmacoEconomics Spanish Research Articles 11:2, pages 51-60.
Crossref
Crossref
Andrew N. Davies. (2014) Breakthrough Cancer Pain. Current Pain and Headache Reports 18:6.
Crossref
Crossref
Claire Combe, Cindy Bourne, Marie Chiganne, Marie Geneste, Hassan Hida & Catherine Lacroix. (2014) Fentanyl transmuqueux : évaluation pratique de son utilisation auprès des patients et des soignants. Médecine Palliative : Soins de Support - Accompagnement - Éthique 13:2, pages 77-83.
Crossref
Crossref
Giovambattista Zeppetella, Andrew Davies, Indra Eijgelshoven & Jeroen P. Jansen. (2014) A Network Meta-Analysis of the Efficacy of Opioid Analgesics for the Management of Breakthrough Cancer Pain Episodes. Journal of Pain and Symptom Management 47:4, pages 772-785.e5.
Crossref
Crossref
T. Beutlhauser, J. Oeltjenbruns & M. Schäfer. (2014) Durchbruchschmerzen und kurz wirksame OpioideBreakthrough pain and short-acting opioids. Wiener klinisches Magazin 17:2, pages 6-15.
Crossref
Crossref
Robert H. Dworkin, Michael P. McDermott, John T. Farrar, Alec B. O'Connor & Stephen Senn. (2014) Interpreting patient treatment response in analgesic clinical trials: Implications for genotyping, phenotyping, and personalized pain treatment. Pain 155:3, pages 457-460.
Crossref
Crossref
Stanislava Novotna, Klara Valentova, Jitka Fricova, Eva Richterova, Sarka Harabisova, Françoise Bullier & Françoise Trinquet. (2014) A Randomized, Placebo-Controlled Study of a New Sublingual Formulation of Fentanyl Citrate (Fentanyl Ethypharm) for Breakthrough Pain in Opioid-Treated Patients With Cancer. Clinical Therapeutics 36:3, pages 357-367.
Crossref
Crossref
Silvia Deandrea, Oscar Corli, Dario Consonni, Walter Villani, Maria Teresa Greco & Giovanni Apolone. (2014) Prevalence of Breakthrough Cancer Pain: A Systematic Review and a Pooled Analysis of Published Literature. Journal of Pain and Symptom Management 47:1, pages 57-76.
Crossref
Crossref
Ignacio Velázquez Rivera, José Carlos Muñoz Garrido, Pilar García Velasco, Inmaculada España Ximénez de Enciso & Lourdes Velázquez Clavarana. (2014) Efficacy of Sublingual Fentanyl vs. Oral Morphine for Cancer-Related Breakthrough Pain. Advances in Therapy 31:1, pages 107-117.
Crossref
Crossref
Srinivas Nalamachu. (2013) An Evaluation of Total Disintegration Time for Three Different Doses of Sublingual Fentanyl Tablets in Patients with Breakthrough Pain. Pain and Therapy 2:2, pages 121-128.
Crossref
Crossref
Giovambattista Zeppetella & Andrew N Davies. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
K. McWilliams & M. Fallon. (2013) Fast-acting fentanyl preparations and pain management. QJM 106:10, pages 887-890.
Crossref
Crossref
Ravi Jandhyala, John R. Fullarton & Michael I. Bennett. (2013) Efficacy of Rapid-Onset Oral Fentanyl Formulations vs. Oral Morphine for Cancer-Related Breakthrough Pain: A Meta-Analysis of Comparative Trials. Journal of Pain and Symptom Management 46:4, pages 573-580.
Crossref
Crossref
Jordi Guitart, Isabel Vargas, Vicente De Sanctis, Julia Ferreras, Jose Fuentes, Rafael Salazar, Juan M. Vázquez, Jordi Folch, Jordi Moya, Hermann Ribera, Francisco Rodelas, Albert Tomás, María Arilla, Joan Coma, Teresa Aberasturi, Dolores Sintes & Ester Lombán. (2013) Efficacy and Safety of Sublingual Fentanyl Orally Disintegrating Tablets in Patients with Breakthrough Pain: Multicentre Prospective Study. Clinical Drug Investigation 33:9, pages 675-683.
Crossref
Crossref
Y. Escobar, A. Mañas, J. Juliá, R. Gálvez, F. Zaragozá, C. Margarit, R. López, A. Casas, A. Antón & J. J. Cruz. (2012) Optimal management of breakthrough cancer pain (BCP). Clinical and Translational Oncology 15:7, pages 526-534.
Crossref
Crossref
T. Beutlhauser, J. Oeltjenbruns & M. Schäfer. (2013) Durchbruchschmerzen und kurz wirksame OpioideBreakthrough pain and short-acting opioids. Der Anaesthesist 62:6, pages 431-439.
Crossref
Crossref
S. Wirz, C.H.R. Wiese, M. Zimmermann, U. Junker, E. Heuser-Grannemann & M. Schenk. (2013) Schnell freisetzende FentanylapplikationsformenRapid release fentanyl administration forms. Der Schmerz 27:1, pages 76-80.
Crossref
Crossref
Robert Horton & Graeme Rocker. 2013. Evidence-Based Practice in Palliative Medicine. Evidence-Based Practice in Palliative Medicine
111
119
.
Donald R TaylorDonald Taylor. 2013. Managing Cancer Breakthrough Pain. Managing Cancer Breakthrough Pain
29
66
.
Srinivas R. Nalamachu, Richard L. Rauck, Mark S. Wallace, David Hassman & Julian Howell. (2012) Successful Dose Finding with Sublingual Fentanyl Tablet: Combined Results from 2 Open‐Label Titration Studies. Pain Practice 12:6, pages 449-456.
Crossref
Crossref
Robert Twycross, Eric E. Prommer, Mary Mihalyo & Andrew Wilcock. (2012) Fentanyl (transmucosal). Journal of Pain and Symptom Management 44:1, pages 131-149.
Crossref
Crossref
Howard Smith. (2012) A Comprehensive Review of Rapid-Onset Opioids for Breakthrough Pain. CNS Drugs 26:6, pages 509-535.
Crossref
Crossref
Stanislas Grassin-Delyle, Amparo Buenestado, Emmanuel Naline, Christophe Faisy, Sabine Blouquit-Laye, Louis-Jean Couderc, Morgan Le Guen, Marc Fischler & Philippe Devillier. (2012) Intranasal drug delivery: An efficient and non-invasive route for systemic administration. Pharmacology & Therapeutics 134:3, pages 366-379.
Crossref
Crossref
Sebastiano Mercadante. (2012) The Authorʼs Reply. Drugs 72:7, pages 1009-1010.
Crossref
Crossref
Julian Howell. (2012) Pharmacotherapy for Breakthrough Cancer Pain. Drugs 72:7, pages 1009.
Crossref
Crossref
Mona Darwish & Fang Xie. (2011) Pharmacokinetics of Fentanyl Buccal Tablet: A Pooled Analysis and Review. Pain Practice 12:4, pages 307-314.
Crossref
Crossref
Frank Porecca & Tamara KingSebastiano Mercadante. 2012. Analgesics for Cancer Pain. Analgesics for Cancer Pain
72
80
.
Sebastiano Mercadante. (2012) Pharmacotherapy for Breakthrough Cancer Pain. Drugs 72:2, pages 181-190.
Crossref
Crossref
Frédéric Guirimand. (2011) Le fentanyl en soins palliatifs : de la pharmacologie à la clinique. Médecine Palliative : Soins de Support - Accompagnement - Éthique 10:6, pages 296-305.
Crossref
Crossref
Sebastiano Mercadante. (2011) The use of rapid onset opioids for breakthrough cancer pain: The challenge of its dosing. Critical Reviews in Oncology/Hematology 80:3, pages 460-465.
Crossref
Crossref
Sebastiano Mercadante. (2011) Emerging drugs for cancer-related pain. Supportive Care in Cancer 19:12, pages 1887-1893.
Crossref
Crossref
Sebastiano Mercadante. (2011) Rapid onset opioids for breakthrough pain: Titrating or not titrating, this is the question!. European Journal of Pain Supplements 5:S2, pages 443-447.
Crossref
Crossref
Frank Elsner, Giovambattista Zeppetella, Josep Porta-Sales & Ignacio Tagarro. (2011) Newer Generation Fentanyl Transmucosal Products for Breakthrough Pain in Opioid-Tolerant Cancer Patients. Clinical Drug Investigation 31:9, pages 605-618.
Crossref
Crossref
Nicola Lister, Steve Warrington, Malcolm Boyce, Catarina Eriksson, Masami Tamaoka & John Kilborn. (2011) Pharmacokinetics, Safety, and Tolerability of Ascending Doses of Sublingual Fentanyl, With and Without Naltrexone, in Japanese Subjects. The Journal of Clinical Pharmacology 51:8, pages 1195-1204.
Crossref
Crossref
G. Zeppetella. (2011) Breakthrough Pain in Cancer Patients. Clinical Oncology 23:6, pages 393-398.
Crossref
Crossref
Sebastiano Mercadante. (2011) Managing Breakthrough Pain. Current Pain and Headache Reports 15:4, pages 244-249.
Crossref
Crossref
Andrew N Davies. (2011) The management of breakthrough cancer pain. British Journal of Nursing 20:13, pages 803-807.
Crossref
Crossref
&NA;. (2011) Fentanyl sublingual tablet: a guide to its use in breakthrough pain in opioid-tolerant adults with cancer. Drugs & Therapy Perspectives 27:7, pages 6-9.
Crossref
Crossref
J. Keßler & H.J. Bardenheuer. (2011) TumordurchbruchschmerzCancer breakthrough pain. Der Anaesthesist 60:7, pages 674-682.
Crossref
Crossref
Ulrich R. Kleeberg, Marilène Filbet & Giovambattista Zeppetella. (2011) Fentanyl Buccal Tablet for Breakthrough Cancer Pain: Why Titrate?. Pain Practice 11:2, pages 185-190.
Crossref
Crossref
. (2011) Current World Literature. Current Opinion in Supportive & Palliative Care 5:1, pages 65-68.
Crossref
Crossref
Andrew Dickman. (2011) Integrated strategies for the successful management of breakthrough cancer pain. Current Opinion in Supportive & Palliative Care 5:1, pages 8-14.
Crossref
Crossref
Gagan Mahajan, Samir Sheth & Mark Holtsman. 2011. Essentials of Pain Medicine. Essentials of Pain Medicine
85
96
.
Claudine M. Chwieduk & Kate McKeage. (2010) Fentanyl Sublingual. Drugs 70:17, pages 2281-2288.
Crossref
Crossref
Neil A HagenDwight E Moulin, Penny MA Brasher, Patricia D Biondo, Misha Eliasziw, Sharon M Watanabe & Carla R Stiles. (2010) A formal feasibility study of sublingual methadone for breakthrough cancer pain. Palliative Medicine 24:7, pages 696-706.
Crossref
Crossref
Dominique A Lossignol & Cristina Dumitrescu. (2010) Breakthrough pain: progress in management. Current Opinion in Oncology 22:4, pages 302-306.
Crossref
Crossref
Josep Porta-Sales, Cristina Garzón Rodríguez, Joaquín Julià Torras & Miquel Casals Merchán. (2010) Dolor irruptivo en cáncer. Medicina Clínica 135:6, pages 280-285.
Crossref
Crossref
Robert Horton & Graeme Rocker. (2010) Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease. Current Opinion in Supportive & Palliative Care 4:2, pages 56-62.
Crossref
Crossref